Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...
Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
Taking darunavir/cobicistat (Prezcobix) with a new HIV drug known as BMS-663068, which is currently being studied, was safe and did not cause any serious reactions in two studies.
Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.